首页> 外文OA文献 >Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria

【2h】

Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria

机译：非洲裔美国人和白人的特征和心血管疾病事件率，以升高风险（傅里叶）审判标准（傅里叶）试验标准的受试者进一步心血管成果研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Lisandro D. Colantonio; Keri L. Monda; Robert S. Rosenson; Todd M. Brown; Katherine E. Mues; George Howard; Monika M. Safford; Larisa Yedigarova; Michael E. Farkouh; Paul Muntner;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria [J] . Colantonio Lisandro D., Monda Keri L., Rosenson Robert S., Cardiovascular drugs and therapy . 2019,第2期

机译：非洲裔美国人和白人的特征和心血管疾病事件率，以升高风险（傅里叶）审判标准（傅里叶）试验标准的受试者进一步心血管成果研究
2. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) [J] . Bonaca Marc P., Nault Patrice, Giugliano Robert P., Circulation: An Official Journal of the American Heart Association . 2018,第4期

机译：低密度脂蛋白胆固醇降低了外周动脉疾病患者的Evolocumab和结果：傅里叶试验的见解（进一步的心血管结果与PCSK9在升高风险的受试者中的抑制作用）
3. Response by Bonaca and Sabatine to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)" [J] . Bonaca Marc P., Sabatine Marc S. Circulation: An Official Journal of the American Heart Association . 2018,第2期

机译：Bonaca和Sabatine对文章的信件，“低密度脂蛋白胆固醇降低与外周血疾病患者的Evolocumab和结果：来自傅里叶试验的见解（进一步的心血管结果与PCSK9在风险升高的受试者中的抑制作用）”
4. Low fitness phenotype and cardiovascular disease risks in African American women [D] . Owen, Jurine H. 2012

机译：非洲裔美国女性的低健身表型和心血管疾病风险
5. How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area [O] . Silvia Canivell, Manel Mata-Cases, Bogdan Vlacho, 2019

机译：有多少2型糖尿病患者符合使用SGLT2抑制剂进行心血管结果试验的纳入标准？来自地中海地区人口数据库的估计
6. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 inhibition in subjects with elevated risk) [O] . Bonaca, MP, Nault, P, Giugliano, RP, 2017

机译：使用evolocumab降低低密度脂蛋白胆固醇和外周动脉疾病患者的结果：来自FOURIER试验的见解（进一步的心血管结果研究，pCsK9抑制风险升高的受试者）

Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria

著录项

相似文献

相关主题

期刊订阅